The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balboa, M. A.
Right arrow Articles by Balsinde, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balboa, M. A.
Right arrow Articles by Balsinde, J.
The Journal of Immunology, 2003, 171: 989-994.
Copyright © 2003 by The American Association of Immunologists

Amplification Mechanisms of Inflammation: Paracrine Stimulation of Arachidonic Acid Mobilization by Secreted Phospholipase A2 Is Regulated by Cytosolic Phospholipase A2-Derived Hydroperoxyeicosatetraenoic Acid1

María A. Balboa, Rebeca Pérez and Jesús Balsinde2

Institute of Molecular Biology and Genetics, University of Valladolid School of Medicine, Valladolid, Spain


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In macrophages and other major immunoinflammatory cells, two phospholipase A2 (PLA2) enzymes act in concert to mobilize arachidonic acid (AA) for immediate PG synthesis, namely group IV cytosolic phospholipase A2 (cPLA2) and a secreted phospholipase A2 (sPLA2). In this study, the molecular mechanism underlying cross-talk between the two PLA2s during paracrine signaling has been investigated. U937 macrophage-like cells respond to Con A by releasing AA in a cPLA2-dependent manner, and addition of exogenous group V sPLA2 to the activated cells increases the release. This sPLA2 effect is abolished if the cells are pretreated with cPLA2 inhibitors, but is restored by adding exogenous free AA. Inhibitors of cyclooxygenase and 5-lipoxygenase have no effect on the response to sPLA2. In contrast, ebselen strongly blocks it. Reconstitution experiments conducted in pyrrophenone-treated cells to abolish cPLA2 activity reveal that 12- and 15-hydroperoxyeicosatetraenoic acid (HPETE) are able to restore the sPLA2 response to levels found in cells displaying normal cPLA2 activity. Moreover, 12- and 15-HPETE are able to enhance sPLA2 activity in vitro, using a natural membrane assay. Neither of these effects is mimicked by 12- or 15-hydroxyeicosatetraenoic acid, indicating that the hydroperoxy group of HPETE is responsible for its biological activity. Collectively, these results establish a role for 12/15-HPETE as an endogenous activator of sPLA2-mediated phospholipolysis during paracrine stimulation of macrophages and identify the mechanism that connects sPLA2 with cPLA2 for a full AA mobilization response.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The phospholipase A2 (PLA2)3 superfamily represents a heterogeneous group of enzymes with key roles in inflammation whose common feature is to hydrolyze the fatty acid present at the sn-2 position of phospholipids (1, 2). Multiple forms of PLA2 have been described in mammalian tissues, including several forms of secreted PLA2 (sPLA2) (3), group IV Ca2+-dependent cytosolic PLA2 (cPLA2) (4), and group VI Ca2+-independent PLA2 (5). Of those, cPLA2 and two of the sPLA2 enzymes, namely groups IIA and V, have repeatedly been shown to be responsible for generating free arachidonic acid (AA) for PG synthesis (6, 7).

An interesting feature of the AA release process is that cross-talk appears to exist between the PLA2 involved. During stimulation of the cells with agents that promote an immediate AA mobilization response, cPLA2 activation precedes and appears to be required for the subsequent action of sPLA2 (either group IIA or V) (8, 9, 10, 11, 12). The first evidence in support of this view was provided by studies in macrophages showing that the sPLA2-dependent release of AA was blocked by cPLA2 inhibitors, and restored by elevating the intracellular levels of free AA by exogenous addition of the fatty acid, which mimics cPLA2 activation (8, 9). These results were later confirmed in other cell types (10, 11), and also by transfection studies showing a synergistic sPLA2-dependent AA release in cells overexpressing cPLA2 (12). Because sPLA2 activity is particularly sensitive to the physical state of the membrane, different events that alter membrane dynamics, such as ceramide generation (13), membrane oxidation (14), and loss of membrane asymmetry (15, 16), have been proposed as possible mechanisms involved in facilitating sPLA2 hydrolysis of the agonist-stimulated cellular membranes. However, the factor that intermediates between cPLA2 and sPLA2 has not been identified.

To understand better the interplay between cPLA2 and sPLA2 in AA mobilization in macrophages, we have examined the effects of exogenous group V PLA2 on AA mobilization from activated human U937 macrophage-like cells. These settings mimic an instance of paracrine amplification of the inflammatory response in that exogenous sPLA2 being released to the inflammatory foci acts on neighboring cells to increase the response.

Activated U937 cells exhibit an immediate AA release response when exposed to a variety of receptor-mediated and soluble agonists. This AA release is sensitive to inhibitors of cPLA2, but not to inhibitors of other PLA2s, implying that only cPLA2 is responsible for the release (17, 18, 19). Results described in this work identify 12/15-hydroperoxyeicosatetraenoic acid (12/15-HPETE) as the cPLA2-downstream product that enables exogenous group V sPLA2 to properly act on the membranes of activated U937 macrophages.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Materials

The [5, 6, 8, 9, 11, 12, 14, 15-3H]AA (100 Ci/mmol) was from Amersham (Arlington Heights, IL). The 12(S)-HPETE, 15(S)-HPETE, 12-hydroxyeicosatetraenoic acid (12-HETE), and 15-HETE were purchased from Cayman (Ann Arbor, MI). Lipoxygenase inhibitors were from BioMol (Plymouth Meeting, PA). DNA polymerase was from BioTools (Madrid, Spain). Primers for PCR were from MWG-Biotech AG (Ebersberg, Germany). Recombinant rat group V sPLA2 was generously provided by A. Aarsman (Utrecht University, Utrecht, The Netherlands) (20). The specific cPLA2{alpha} inhibitor pyrrophenone was generously provided by K. Seno (Shionogi, Osaka, Japan) (21). All other reagents were from Sigma-Aldrich (St. Louis, MO).

Cell culture

U937 cells were maintained in RPMI 1640 medium supplemented with 10% (v/v) FCS, 2 mM glutamine, penicillin (100 U/ml), and streptomycin (100 µg/ml). The cells were incubated at 37°C in a humidified atmosphere of CO2/O2 (1:19) at a cell density of 0.5–1 x 106 cells/ml in 12-well plastic culture dishes (Costar, Cambridge, MA). Cell differentiation was induced by treating the cells with 35 ng/ml PMA for 24 h (22, 23).

AA release experiments

The cells were labeled with 0.5 µCi/ml [3H]AA for 18 h. After this period, the cells were washed and placed in serum-free medium for 1 h before the addition of 100 µg/ml Con A in the presence of 0.5 mg/ml BSA. When free AA, HPETEs, or HETEs were added to the cells, they were dissolved in ethanol. Appropriate controls were conducted to exclude an effect of the solvent. The supernatants were removed, cleared of cells by centrifugation, and assayed for radioactivity by liquid scintillation counting.

Enzyme assays

For the measurement of cellular iPLA2, aliquots of U937 cell homogenates were incubated for 2 h at 37°C in 100 mM HEPES (pH 7.5) containing 5 mM EDTA and 100 µM labeled phospholipid substrate (1-palmitoyl-2-[3H]palmitoylglycero-3-phosphocholine, sp. act. 60 Ci/mmol; American Radiolabeled Chemicals, St. Louis, MO) in a final volume of 150 µl. The phospholipid substrate was used in the form of sonicated vesicles in buffer. For group V sPLA2 enzyme activity assay, the mammalian membrane substrate assay described by Diez et al. (24) was used.

RT-PCR

cDNA from U937 cells was produced using the kit Cells-to-cDNA (Ambion, Austin, TX), following the manufacturer’s instructions. The cDNA was then amplified by PCR using the following primers: 15-LOX (15-LOX-1), upstream primer (5'-GAGTTGACTTTGAGGTTTCGC-3'), downstream primer (5'-GCCCGTCTGTCTTATAGTGG-3') (25); 15-LOX-2, upstream primer (5'-TGCCTCTCGCCATCCAGCT-3'), downstream primer (5'-TGTTCCCCTGGGATTTAGATGGA-3') (26); and 12-LOX, upstream primer (5'-CGTAAGGATGATCTACCTCC-3'), downstream primer (5'-TTGGGGTTGGAGAGCTGGGG) (27). The expected sizes for PCR products using these primers were: 952, 1065, and 519 bp, respectively. PCR conditions were: 30–35 cycles, denaturation at 94°C for 1–2 min; annealing at 58°C for 75 min for 15-LOX, 60°C for 1 min for 15-LOX-2, and 63°C for 1 min for 12-LOX, and extension at 72°C for 2 min. An additional extension at 72°C for 10 min was performed at the end of the cycles. The amplified DNA was analyzed by 2% agarose gel electrophoresis and visualized by ethidium bromide.

Separation of AA metabolites

For these experiments, the cells were labeled with 5 µCi [3H]AA for 18 h and the stimulations were conducted in the absence of albumin. The supernatant was acidified to pH 3.5 with 5 M formic acid, and extracted twice with 3 ml of isopropanol-diethyl ether (1:1.5). The organic phase was dried under a stream of nitrogen, and the residue was dissolved in a few drops of chloroform-methanol (2:1, v/v) and analyzed by reverse-phase HPLC. Separation of lipoxygenase metabolites was performed on a 4.6 x 250-mm ODS reverse-phase column (Beckman, Palo Alto, CA), using an isocratic mobile phase of methanol-water-acetic acid (70:30:1) at a flow rate of 0.5 ml/min. Fractions of 0.5 ml were collected, and radioactivity content was measured by liquid scintillation counting. Retention times of the different products were identified by coelution with authentic standards (Cayman).

Data presentation

Assays were conducted in triplicate. Each set of experiments was repeated at least three times with similar results. Unless otherwise indicated, the data presented are from representative experiments, and are shown as means ± SD.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Exogenous group V sPLA2 effects on AA release from U937 cells

When PMA-differentiated U937 cells are stimulated by Con A, immediate AA release occurs by a mechanism that is entirely attributable to cPLA2 activation, with no involvement of the one other PLA2 that these cells express, namely iPLA2 (18, 19). This conclusion is based on the complete inhibition of the AA release response by the specific cPLA2 inhibitor pyrrophenone at concentrations higher than 0.5 µM (19), and the lack of any detectable effect of the iPLA2 inhibitor bromoenol lactone even at concentrations as high as 25 µM (18). U937 cells have been reported not to exhibit measurable sPLA2 activity (17, 28). In accordance with this, we have not detected expression of groups IB, IIA, IIC, IID, IIE, IIF, III, V, and X in U937 cells by RT-PCR (M. A. Balboa and J. Balsinde, unpublished data). Fig. 1A shows that pyrrophenone concentrations equal to those leading to complete inhibition of Con A-induced AA release had no effect on the iPLA2 activity of U937 cell homogenates, as measured in an in vitro assay. Even at concentrations of 10 µM, pyrrophenone exerted little effect on cellular iPLA2 activity (Fig. 1B). At the same concentrations, pyrrophenone also failed to minimally affect the activity of pure group V sPLA2 (Fig. 1B).



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 1. Effect of pyrrophenone on PLA2 activities. A, Homogenates from U937 cells (•) were assayed for calcium-independent PLA2 activity in the presence of the indicated concentrations of pyrrophenone. {circ}, Denote control incubations in the absence of homogenate. B, Recombinant group V sPLA2 was assayed for activity using a natural membrane as substrate. [3H]AA-labeled membranes were incubated without ({circ}) or with (•) 15 nM group V sPLA2 for 1 h in the presence of the indicated concentrations of pyrrophenone.

 
Addition of exogenous group V sPLA2 to the Con A-activated U937 cells resulted in a dramatic increase in the amount of [3H]AA mobilized (Fig. 2). Such an elevated response was inhibited by the specific cPLA2 inhibitor pyrrophenone (Fig. 2), suggesting that in U937 macrophages, cPLA2 activation modulates sPLA2. The sPLA2-dependent AA release was blocked by the specific inhibitor LY311727, indicating that the hydrolytic activity of the enzyme is required for the response to take place (Fig. 2).



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 2. Exogenous sPLA2-induced [3H]AA release from U937 macrophage-like cells. The cells were untreated ({square}) or treated with 100 µg/ml Con A or 100 µg/ml Con A plus 15 nM group V sPLA2, as indicated ( ), for 15 min in the absence or presence of the indicated inhibitors. Pyrrophenone (Pyrr) was used at 1 µM. LY311727 (LY) was used at 25 µM.

 
Role of 12/15-HPETE in facilitating sPLA2 activity

The above data indicate that in common with other cell types (8, 9, 10, 11, 12), activation of cPLA2 in U937 cells appears to facilitate the action of sPLA2 on cellular membranes. To further stress this notion, [3H]oleic acid release experiments were conducted. cPLA2 releases little, if anything, of this fatty acid, whereas sPLA2 does it readily (29, 30). Thus, determination of [3H]oleic acid release allows one to separate the contribution of sPLA2 to phospholipid hydrolysis from the one of cPLA2 and, in turn, provides a straightforward tool to study the effect of cPLA2 inhibition on sPLA2 activation. Fig. 3 shows that U937 cells exposed to exogenous group V sPLA2 released modest quantities of [3H]oleic acid. Such a release was completely blocked by LY311727, thus confirming that it was actually due to sPLA2 (not shown). When the cells were activated by Con A and then exposed to exogenous sPLA2, a marked potentiation of the response occurred. Con A-activated cells released no oleic acid in the absence of exogenous sPLA2, in agreement with previous data (19). Importantly, the enhanced response was blocked by treating the cells with the cPLA2 inhibitor pyrrophenone (Fig. 3). The inhibitory effect of pyrrophenone could be reversed by exposing the cells to 1 µM exogenous AA for 2 min before sPLA2 addition. At the concentration used, exogenous AA did not exert any effect on its own (Fig. 3). Addition of lyso-phosphatidylcholine to the cPLA2-activity-deficient cells did not restore the sPLA2 effect (Fig. 3). These results suggest that cPLA2-derived AA, or an oxygenated metabolite, plays a role in mediating the action of sPLA2 on cellular membranes.



View larger version (46K):
[in this window]
[in a new window]
  		FIGURE 3. Arachidonic acid restores the enhancing effect of exogenous sPLA2 on [3H]oleic acid mobilization in activated U937 macrophage-like cells. The cells were preincubated with 1 µM pyrrophenone where indicated. Subsequently, the cells were stimulated by Con A (100 µg/ml) in the absence or presence of 15 nM exogenous group V sPLA2 and in the absence or presence of 1 µM AA or 10 µM lyso-phosphatidylcholine (LysoPC), as indicated.

 
Fig. 4A shows that the contribution of exogenous sPLA2 to total [3H]AA mobilization in cells exposed to both Con A and exogenous sPLA2 was markedly reduced by the unspecific 15-lipoxygenase inhibitor ebselen (31), but not by inhibitors of cyclooxygenase (aspirin), 5-lipoxygenase-activating protein (MK-886) (32), or platelet-type 12-lipoxygenase (baicalein) (33). Moreover, inhibition by ebselen could be overcome by addition of 15-HPETE, the immediate product of 15-lipoxygenase action on free AA. The 15-HETE was considerably less effective than 15-HPETE in restoring the sPLA2 effect, and 12-HPETE also restored it completely (Fig. 4B). These results suggest that the hydroperoxy group of 15-HPETE (and of 12-HPETE) is responsible for the enhancing effect on sPLA2.



View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 4. Effect of inhibitors of AA metabolism on [3H]AA release in activated U937 macrophages. A, The cells were untreated ({square}) or treated with 100 µg/ml Con A or 100 µg/ml Con A plus 15 nM group V sPLA2, as indicated ( ), for 15 min in the absence or presence of the indicated inhibitors. All of the inhibitors were used at 25 µM. B, The cells were incubated with 25 µM ebselen where indicated. Subsequently, the cells were treated with () or without ({square}) 100 µg/ml Con A in the presence or absence of 15 nM sPLA2, 0.5 µM 15-HPETE, 0.5 µM 15-HETE, or 0.5 µM 12-HPETE, as indicated.

 
The 15-HPETE also enabled sPLA2 action on cellular membranes in cells deficient in cPLA2 activity, and 12-HPETE reproduced the effect (Fig. 5). Collectively, the results of Figs. 4 and 5 suggest that 12/15-HPETE is/are the factor(s) that, lying downstream of cPLA2, enables sPLA2 to properly act on cellular membranes. The 15-HPETE and 12-HPETE are both produced by reticulocyte-type 15-lipoxygenase in human myeloid cells, with 15-HPETE being the major product (34). However, because the relative proportion of products synthesized varies among species, this enzyme is also frequently called 12/15-lipoxygenase, and hereinafter it will be referred as such. This enzyme is also called 15-lipoxygenase-1 to distinguish it from the more recently described 15-lipoxygenase-2 (26). RT-PCR analysis of RNA from PMA-differentiated U937 cells revealed that these cells did express 12/15-lipoxygenase (Fig. 6A). PCR product specificity was confirmed by DNA sequence analysis. No expression of 12-lipoxygenase (platelet type) or 15-lipoxygenase-2 could be demonstrated (data not shown).



View larger version (36K):
[in this window]
[in a new window]
  		FIGURE 5. The 12- and 15-HPETE restore the enhancing effect of exogenous sPLA2 on [3H]AA mobilization in activated U937 macrophages. [3H]AA-labeled Con A-activated cells were preincubated with 1 µM pyrrophenone for 15 min where indicated. Subsequently, 0.5 µM 15-HPETE or 12-HPETE was added 3 min before adding 15 nM group V sPLA2, as indicated. To highlight the contribution of sPLA2 to the [3H]AA release, the responses in the absence of sPLA2 were subtracted from those in the presence of sPLA2 at each condition.

 


View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 6. Involvement of 12/15-lipoxygenase in AA mobilization in U937 cells. A, RT-PCR analysis of 12/15-lipoxygenase in U937 cells. cDNA from U937 cells was obtained and amplified by PCR using the primers set described in Materials and Methods. Lane 1, Corresponds to a 1000-bp ladder; lane 2, corresponds to the analysis of the product (952 bp) obtained by PCR from U937 cDNA. B, The 12- and 15-HPETE production by activated U937 macrophages. The [3H]AA-labeled cells were treated with 100 µg/ml Con A for 15 min in the presence (gray bars) or absence (open bars) of 1 µM pyrrophenone, as indicated. The 12/15-HPETE production was determined by reverse-phase HPLC, as described in Materials and Methods.

 
Production of 15-HPETE by activated U937 cells

Reverse-phase HPLC determinations were conducted to verify whether activated U937 macrophage-like cells produced 12/15-lipoxygenase metabolites in a cPLA2-dependent manner. Stimulation of the [3H]AA-labeled U937 cells with Con A resulted in a significant production of 15-[3H]HPETE (Fig. 6B). Low levels of 12-[3H]HPETE were also detected (Fig. 6B). Unstimulated [3H]AA-labeled U937 cells did not produce significant amounts of these products. Importantly, when the experiments were conducted in the presence of pyrrophenone to block cPLA2 activity, a strong inhibition of 12/15-[3H]HPETE production was detected (93 ± 2% inhibition, mean ± SD, n = 3). Thus, activated cells produce 12/15-lipoxygenase products downstream of cPLA2 activation.

The 12/15-HPETE enhance sPLA2 activity

The 12/15-lipoxygenase is known to catalyze endogenous membrane oxidation, which may have profound effects on cellular physiology (34). Given that sPLA2 are particularly sensitive to physical changes of the membranes (35), it is likely that the hydroperoxy metabolites produced by 12/15-lipoxygenase may act to influence sPLA2 activity by altering membrane structure. To investigate this possibility, sPLA2 activity measurements were conducted using the natural membrane assay described by Diez et al. (24). In this system, purified [3H]AA-labeled membranes are used as substrate. Addition of 15-HPETE to the assay mix resulted in a marked increase in sPLA2 activity (Fig. 7). Such an increase was not observed if 15-HETE was added instead. The 12-HPETE exerted the same stimulatory effect as 15-HPETE. As a positive control, H2O2-oxidized membranes were used (19), and marked increases in sPLA2 activity were observed as well (data not shown). Thus, membrane peroxidation sensitizes membranes to sPLA2 attack.



View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 7. The 12/15-HPETE enhance sPLA2 activity using a natural membrane as substrate. [3H]AA-labeled membranes were incubated with ({blacksquare}) or without ({square}) 15 nM group V sPLA2 for 1 h in the presence of 0.5 µM 12/15-HETE, 0.5 µM 12/15-HPETE, or neither, as indicated.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Major immunoinflammatory cells such as macrophages and mast cells mobilize AA for PG production in two temporally distinct phases, namely the immediate and delayed pathways (6, 10, 35, 36, 37). The immediate pathway, which is typically triggered by Ca2+-mobilizing agonists, goes on for short periods of time (up to 1 h) and occurs at the expense of pre-existing effectors. The delayed pathway, spanning several hours, is strikingly dependent on protein synthesis. Both pathways appear to involve two PLA2 effectors, namely cPLA2 and sPLA2, although the mechanisms dramatically differ. In general terms, cPLA2 appears to act as the initiator and key regulator of the response, while sPLA2 amplifies the cPLA2-generated signal. The sPLA2 may act both as an autocrine and paracrine effector (i.e., on the same cells that secreted it, or on neighboring cells), ensuring in this manner an efficient amplification of the response (6, 10, 30, 35, 36, 37).

In this work, we have studied the interactions between cPLA2 and exogenous sPLA2 during the immediate AA release response triggered by Con A on U937 macrophage-like cells. AA release in this cellular system depends on cPLA2 activation, as judged by complete inhibition of the response by the highly selective cPLA2 inhibitor pyrrophenone (19) (Fig. 1). Although no sPLA2 activity has been demonstrated to occur in U937 cells (28), this study shows that sPLA2 can still participate in the immediate response of the U937 cells if applied exogenously. This strategy is pathophysiologically sound in that it mimics a paracrine mechanism for amplification of the inflammatory response. In turn, the use of exogenous enzyme provides a straightforward means to study the influence of cPLA2 activation on the action of sPLA2.

Group V sPLA2 is produced by human and murine macrophages and mast cells, and has been repeatedly shown to play key roles in proinflammatory AA signaling (38) and, importantly, to be capable of activating cells in the vicinity of those that secreted it (25). Unlike the group IIA enzyme, group V sPLA2 can act on the outer membrane of otherwise unstimulated cells (24, 25). However, the effect is more prominent on agonist-activated cells (39), reflecting the need for some kind of membrane rearrangement for group V sPLA2 to fully express its hydrolytic activity (35).

Our previous studies in murine macrophages demonstrated that the elevated activity that group V sPLA2 displays toward agonist-activated cells can be greatly diminished if cellular cPLA2 activity is blocked, indicating the existence of cross-talk between the two signaling PLA2s (8, 9). Importantly, the inhibitory effect of cPLA2 can be overcome by exogenous AA, suggesting that a cPLA2-derived AA metabolite intermediates between cPLA2 and sPLA2 (8, 9). In this study, we provide direct evidence that such a metabolite is 12/15-HPETE, the immediate product of 12/15-lipoxygenase action on free AA. Thus, cell treatment with ebselen blocks the enhanced action of group V sPLA2 on activated U937 cells, and reconstitution experiments show that overcoming 12/15-lipoxygenase inhibition by exogenous supply of 12/15-HPETE fully restores the action of sPLA2 on the activated cells. Thus, these results support a model whereby agonist activation of cPLA2 results in the immediate generation of free AA, which will be used by 12/15-lipoxygenase to produce 12/15-HPETE. Subsequently, 12/15-HPETE serves a signaling role by enabling full activation of group V sPLA2 and thus allowing for a further amplification of the AA mobilization response.

The sPLA2-activating effect of 12/15-HPETE was not mimicked by 12/15-HETE, indicating that the hydroperoxy group of 12/15-HPETE is responsible for its biological activity. In turn, this clearly suggests a role for 12/15-HPETE-mediated oxidization of membrane phospholipids as the mechanism for membrane sensitization leading to enhanced group V sPLA2 activity. Fully supporting this view, we have found significantly higher sPLA2 activity in vitro when the membrane substrate was pretreated with 12/15-HPETE.

It has been recognized that a prominent biological action of 12/15-lipoxygenase metabolites on cells is to induce lipid peroxidation reactions, to initiate a series of structural membrane changes (34). For this kind of peroxidation reaction, 12/15-lipoxygenase appears to typically act on esterified substrate, not necessarily on the free fatty acid (34). The current results establish, however, that cPLA2 generation of free AA is required, and hence, that the involvement of 12/15-lipoxygenase in sPLA2 activation takes place through the production of free 12/15-HPETE. This confers on the system greater versatility in that the peroxidizing effect of 12/15-HPETE can be exerted at places far away from its site of synthesis. This is important because 12/15-lipoxygenase is an intracellular enzyme, while exogenous sPLA2 acts primarily on the outer surface of the cells (24, 25, 38). Because 12/15-HPETE can readily be taken up and esterified by the cells (40), it could also be envisioned that this metabolite may exit the cells to amplify the inflammatory response.

Although the results of this study have established a cascade of events for full AA mobilization involving the sequential participation of cPLA2, 12/15-lipoxygenase, and sPLA2, elegant studies by Cho and coworkers (30) have demonstrated that in otherwise unstimulated cells, exogenous group V sPLA2 action leads to activation of cPLA2 and the immediate metabolism of free AA by lipoxygenase pathways. It is tempting to speculate that in analogy with the results of our study, part of the hydroperoxy fatty acids produced under these settings (25) may act to enhance sPLA2 attack on cellular membranes and in this manner amplify the immediate response. In contrast, overexpression studies by Kuwata et al. (41) have suggested a role for 12/15-lipoxygenase in regulating the expression of group IIA sPLA2 during the delayed phase of AA mobilization of 3Y1 fibroblastic cells. Although the mechanisms implicating 12/15-lipoxygenase in the immediate (this study) and delayed (41) AA mobilization pathways obviously differ, it is nonetheless striking that the same effectors appear to be used to elicit these two separate responses.


   Acknowledgments
 
We thank Ton Aarsman (Utrecht University) for generously providing us with recombinant group V sPLA2.


   Footnotes
 
1 This work was supported by the Ramón y Cajal Program, Spanish Research Council (to M.A.B.), Grant BMC2001-2244 from the Spanish Ministry of Science and Technology, Grant CSI-4/02 from the Education Department of the Autonomous Government of Castile and León, and Grant 011232 from Fundació La Marató de TV3. R.P. was the recipient of a predoctoral fellowship from the Spanish Ministry of Science and Technology. Back

2 Address correspondence to Dr. Jesús Balsinde, Instituto de Biología y Genética Molecular (IBGM-CSIC), Facultad de Medicina, Universidad de Valladolid, Avenida Ramón y Cajal 7, E-47005 Valladolid, Spain. E-mail address: jbalsinde{at}ibgm.uva.es Back

3 Abbreviations used in this paper: PLA2, phospholipase A2; AA, arachidonic acid; cPLA2, cytosolic PLA2; HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; iPLA2, calcium-independent PLA2; sPLA2, secreted PLA2. Back

Received for publication January 10, 2003. Accepted for publication May 16, 2003.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Balsinde, J., M. V. Winstead, E. A. Dennis. 2002. Phospholipase A2 regulation of arachidonic acid mobilization. FEBS Lett. 531:2.[Medline]
  2. Six, D. A., E. A. Dennis. 2000. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim. Biophys. Acta 1488:1.[Medline]
  3. Valentin, E., G. Lambeau. 2000. Increasing molecular diversity of secreted phospholipases A2 and their receptors and binding proteins. Biochim. Biophys. Acta 1488:59.[Medline]
  4. Leslie, C. C.. 1997. Properties and regulation of cytosolic phospholipase A2. J. Biol. Chem. 272:16709.[Free Full Text]
  5. Winstead, M. V., J. Balsinde, E. A. Dennis. 2000. Calcium-independent phospholipase A2: structure and function. Biochim. Biophys. Acta 1488:28.[Medline]
  6. Balsinde, J., M. A. Balboa, P. A. Insel., E. A. Dennis. 1999. Regulation and inhibition of phospholipase A2. Annu. Rev. Pharmacol. Toxicol. 39:175.[Medline]
  7. Fitzpatrick, F. A., R. Soberman. 2001. Regulated formation of eicosanoids. J. Clin. Invest. 107:1347.[Medline]
  8. Balsinde, J., E. A. Dennis. 1996. Distinct roles in signal transduction for each of the phospholipase A2 enzymes present in P388D1 macrophages. J. Biol. Chem. 271:6758.[Abstract/Free Full Text]
  9. Balsinde, J., M. A. Balboa, E. A. Dennis. 1998. Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2. Proc. Natl. Acad. Sci. USA 95:7951.[Abstract/Free Full Text]
  10. Reddy, S, H. R. Herschman. 1997. Prostaglandin synthase-1 and prostaglandin synthase-2 are coupled to distinct phospholipases for the generation of prostaglandin D2 in activated mast cells. J. Biol. Chem. 272:3231.[Abstract/Free Full Text]
  11. Kambe, T., M. Murakami, I. Kudo. 1999. Polyunsaturated fatty acids potentiate interleukin-1-stimulated arachidonic acid release by cells overexpressing type IIA secretory phospholipase A2. FEBS Lett. 453:81.[Medline]
  12. Murakami, M., S. Shimbara, T. Kambe, H. Kuwata, M. V. Winstead, J. A. Tischfield, I. Kudo. 1998. The functions of five distinct mammalian phospholipase A2s in regulating arachidonic acid release: type IIA and type V secretory phospholipase A2s are functionally redundant and act in concert with cytosolic phospholipase A2. J. Biol. Chem. 273:14411.[Abstract/Free Full Text]
  13. Balsinde, J., M. A. Balboa, E. A. Dennis. 1997. Inflammatory activation of arachidonic acid signaling in murine P388D1 macrophages via sphingomyelin synthesis. J. Biol. Chem. 272:20373.[Abstract/Free Full Text]
  14. Akiba, S., R. Nagatomo, M. Hayama, T. Sato. 1997. Lipid peroxide overcomes the inability of platelet secretory phospholipase A2 to hydrolyze membrane phospholipids in rabbit platelets. J. Biochem. 122:859.[Abstract/Free Full Text]
  15. Murakami, M., T. Kambe, S. Shimbara, K. Higashino, K. Hanasaki, H. Arita, M. Horiguchi, M. Arita, H. Arai, K. Inoue, I. Kudo. 1999. Different functional aspects of the group II subfamily (types IIA and V) and type X secretory phospholipase A2s in regulating arachidonic acid release and prostaglandin generation: implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. J. Biol. Chem. 274:31435.[Abstract/Free Full Text]
  16. Fourcade, O., M. F. Simon, C. Viodé, N. Rugani, F. Leballe, A. Ragab, B. Fournié, H. Chap. 1995. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 80:919.[Medline]
  17. Hsu, F. F., Z. Ma, M. Wohltmann, A. Bohrer, W. Nowatzke, S. Ramanadham, J. Turk. 2000. Electrospray ionization/mass spectrometric analyses of human promonocytic U937 cell glycerolipids and evidence that differentiation is associated with membrane lipid composition changes that facilitate phospholipase A2 activation. J. Biol. Chem. 275:16579.[Abstract/Free Full Text]
  18. Balsinde, J.. 2002. Roles of various phospholipases A2 in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling. Biochem. J. 364:695.[Medline]
  19. Balboa, M. A., J. Balsinde. 2002. Involvement of calcium-independent phospholipase A2 in hydrogen peroxide-induced accumulation of free fatty acids in human U937 cells. J. Biol. Chem. 277:40384.[Abstract/Free Full Text]
  20. Janssen, M. J., L. Vermeulen, H. A. Van der Helm, A. J. Aarsman, A. J. Slotboom, M. R. Egmond. 1999. Enzymatic properties of rat group IIA and V phospholipases A2 compared. Biochim. Biophys. Acta 1440:59.[Medline]
  21. Ono, T., K. Yamada, Y. Chikazawa, M. Ueno, S. Nakamoto, T. Okuno, K. Seno. 2002. Characterization of a novel inhibitor of cytosolic phospholipase A2{alpha}, pyrrophenone. Biochem. J. 363:727.[Medline]
  22. Balsinde, J., F. Mollinedo. 1988. Specific activation by concanavalin A of the superoxide anion generation capacity during U937 cell differentiation. Biochem. Biophys. Res. Commun. 151:802.[Medline]
  23. Balsinde, J., F. Mollinedo. 1990. Induction of the oxidative response and of concanavalin A-binding capacity in maturing human U937 cells. Biochim. Biophys. Acta 1052:90.[Medline]
  24. Diez, E., F. H. Chilton, G. Stroup, R. J. Mayer, J. D. Winkler, A. N. Fonteh. 1994. Fatty acid and phospholipid selectivity of different phospholipase A2 enzymes studied by using a mammalian membrane as substrate. Biochem. J. 301:721.
  25. Nassar, G. M., J. D. Morrows, L. J. Roberts, F. G. Lakkis, K. F. Badr. 1994. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J. Biol. Chem. 269:27631.[Abstract/Free Full Text]
  26. Brash, A. R., W. E. Boeglin, M. S. Chang. 1997. Discovery of a second 15S-lipoxygenase in humans. Proc. Natl. Acad. Sci. USA 94:6148.[Abstract/Free Full Text]
  27. Takahashi, Y., G. R. Reddy, N. Ueda, S. Yamamoto, S. Arase. 1993. Arachidonate 12-lipoxygenase of platelet-type in human epidermal cells. J. Biol. Chem. 268:16443.[Abstract/Free Full Text]
  28. Burke, J. R., L. B. Davern, K. R. Gregor, G. Todderud, J. G. Alford, K. M. Tramposch. 1997. Phosphorylation and calcium influx are not sufficient for the activation of cytosolic phospholipase A2 in U937 cells: requirement for a Gi {alpha}-type G-protein. Biochim. Biophys. Acta 1341:223.[Medline]
  29. Balsinde, J., M. A. Balboa, S. Yedgar, E. A. Dennis. 2000. Group V phospholipase A2-mediated oleic acid mobilization in lipopolysaccharide-stimulated P388D1 macrophages. J. Biol. Chem. 275:4783.[Abstract/Free Full Text]
  30. Kim, K. P., J. D. Rafter, L. Bittova, S. K. Han, Y. Snitko, N. M. Muñoz, A. R. Leff, W. Cho. 2001. Mechanism of human group V phospholipase A2 (PLA2)-induced leukotriene biosynthesis in human neutrophils: a potential role of heparan sulfate binding in PLA2 internalization. J. Biol. Chem. 276:11126.[Abstract/Free Full Text]
  31. Walther, M., H. G. Holzhütter, H. G. Kuban, J. Wiesner, J. Rathman, H. Kühn. 1999. The inhibition of mammalian 15-lipoxygenase by the anti-inflammatory drug ebselen: dual type mechanism involving covalent linkage and alteration of iron ligand sphere. Mol. Pharmacol. 56:196.[Abstract/Free Full Text]
  32. Ford-Hutchinson, A. W.. 1991. FLAP: a novel drug target for inhibiting the synthesis. Trends Pharmacol. Sci. 12:68.[Medline]
  33. Huang, H. C., L. M. Hsieh, H. W. Chen, Y. S. Lin, J. S. Chen. 1994. Effects of baicalein and esculetin on transduction signals and growth expression in T-lymphoid leukemia cells. Eur. J. Pharmacol. 15:73.
  34. Brash, A. R.. 1999. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 274:23679.[Free Full Text]
  35. Murakami, M., Y. Nakatani, G. Atsumi, K. Inoue, I. Kudo. 1997. Regulatory functions of phospholipase A2. Crit. Rev. Immunol. 17:225.[Medline]
  36. Murakami, M., R. Matsumoto, K. F. Arm, J. P. Arm. 1994. Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J. Biol. Chem. 269:22269.[Abstract/Free Full Text]
  37. Murakami, M., C. O. Bingham, R. Matsumoto, K. F. Austen, J. P. Arm. 1995. IgE-dependent activation of cytokine-primed mouse cultured mast cells induces a delayed phase of prostaglandin D2 generation via prostaglandin endoperoxide synthase-2. J. Immunol. 155:4445.[Abstract]
  38. Cho, W.. 2000. Structure, function, and regulation of group V phospholipase A2. Biochim. Biophys. Acta 1488:48.[Medline]
  39. Balsinde, J., M. A. Balboa, E. A. Dennis. 2000. Identification of a third pathway for arachidonic acid mobilization and prostaglandin production in activated P388D1 macrophage-like cells. J. Biol. Chem. 275:22544.[Abstract/Free Full Text]
  40. Pawlowski, N. A., W. A. Scott, M. Andreach, Z. A. Cohn. 1982. Uptake and metabolism of monohydroxy-eicosatetraenoic acids by macrophages. J. Exp. Med. 155:1653.[Abstract/Free Full Text]
  41. Kuwata, H., S. Yamamoto, Y. Miyazaki, S. Shimbara, Y. Nakatani, H. Suzuki, N. Ueda, S. Yamamoto, M. Murakami, I. Kudo. 2000. Studies on a mechanism by which cytosolic phospholipase A2 regulates the expression and function of type IIA secretory phospholipase A2. J. Immunol. 165:4024.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
V. Ruiperez, A. M. Astudillo, M. A. Balboa, and J. Balsinde
Coordinate Regulation of TLR-Mediated Arachidonic Acid Mobilization in Macrophages by Group IVA and Group V Phospholipase A2s
J. Immunol., March 15, 2009; 182(6): 3877 - 3883.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Pindado, J. Balsinde, and M. A. Balboa
TLR3-Dependent Induction of Nitric Oxide Synthase in RAW 264.7 Macrophage-Like Cells via a Cytosolic Phospholipase A2/Cyclooxygenase-2 Pathway
J. Immunol., October 1, 2007; 179(7): 4821 - 4828.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Ruiperez, J. Casas, M. A. Balboa, and J. Balsinde
Group V Phospholipase A2-Derived Lysophosphatidylcholine Mediates Cyclooxygenase-2 Induction in Lipopolysaccharide-Stimulated Macrophages
J. Immunol., July 1, 2007; 179(1): 631 - 638.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Grkovich, C. A. Johnson, M. W. Buczynski, and E. A. Dennis
Lipopolysaccharide-induced Cyclooxygenase-2 Expression in Human U937 Macrophages Is Phosphatidic Acid Phosphohydrolase-1-dependent
J. Biol. Chem., November 3, 2006; 281(44): 32978 - 32987.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Ramoner, T. Putz, H. Gander, A. Rahm, G. Bartsch, C. Schaber, and M. Thurnher
Dendritic-cell activation by secretory phospholipase A2
Blood, May 1, 2005; 105(9): 3583 - 3587.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
D. E. Dove, M. F. Linton, and S. Fazio
ApoE-mediated cholesterol efflux from macrophages: separation of autocrine and paracrine effects
Am J Physiol Cell Physiol, March 1, 2005; 288(3): C586 - C592.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Pawliczak, C. Logun, P. Madara, M. Lawrence, G. Woszczek, A. Ptasinska, M. L. Kowalski, T. Wu, and J. H. Shelhamer
Cytosolic Phospholipase A2 Group IV{alpha} but Not Secreted Phospholipase A2 Group IIA, V, or X Induces Interleukin-8 and Cyclooxygenase-2 Gene and Protein Expression through Peroxisome Proliferator-activated Receptors {gamma} 1 and 2 in Human Lung Cells
J. Biol. Chem., November 19, 2004; 279(47): 48550 - 48561.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Winkler, C. Abletshauser, I. Friedrich, M. M. Hoffmann, H. Wieland, and W. Marz
Fluvastatin Slow-Release Lowers Platelet-Activating Factor Acetyl Hydrolase Activity: A Placebo-Controlled Trial in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1153 - 1159.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balboa, M. A.
Right arrow Articles by Balsinde, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balboa, M. A.
Right arrow Articles by Balsinde, J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS